AbbVie (ABBV) FCF Payout Ratio (QoQ) (2013 - 2026)
AbbVie (ABBV) FCF Payout Ratio (QoQ) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 45.42% |
| Dec 31, 2025 | 35.88% |
| Sep 30, 2025 | -26.45% |
| Jun 30, 2025 | -71.48% |
| Mar 31, 2025 | 412.98% |
| Dec 31, 2024 | -23.04% |
| Sep 30, 2024 | -60.93% |
| Jun 30, 2024 | 88.00% |
| Mar 31, 2024 | 24.79% |
| Dec 31, 2023 | 61.66% |
| Sep 30, 2023 | -16.44% |
| Jun 30, 2023 | -35.46% |
| Mar 31, 2023 | 90.67% |
| Dec 31, 2022 | 2.99% |
| Sep 30, 2022 | -34.60% |
| Jun 30, 2022 | -3.12% |
| Mar 31, 2022 | 12.43% |
| Dec 31, 2021 | 57.83% |
| Sep 30, 2021 | -39.04% |
| Jun 30, 2021 | -0.64% |